A new immunomodulatory therapy for severe sepsis: Ulinastatin plus thymosin α 1

Journal of Intensive Care Medicine

Volumn 24, Issue 1, 2009, Pages 47-53

  Yumin, Li ^a   Hao, Chen ^a   Xun, Li ^a   Wence, Zhou ^a   Minyan, He ^a   Chiriva Internati, M ^b   Wachtel, M S ^b   Frezza, E E ^b  

^a LANZHOU UNIVERSITY   (China)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

APACHE II; Clinical trial; Immunomodulatory therapy; Sepsis; Thymosin 1; Ulinastatin

Indexed keywords

CYTOKINE; PLACEBO; THYMOSIN ALPHA1; ULINASTATIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HOSPITAL ADMISSION; HUMAN; IMMUNOMODULATION; INTENSIVE CARE UNIT; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEPSIS;

ADJUVANTS, IMMUNOLOGIC; ADULT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEPSIS; SURVIVAL RATE; THYMOSIN; TREATMENT OUTCOME; TRYPSIN INHIBITORS;

EID: 58349089304     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066608326970     Document Type: Article

References (50)

1. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992 ; 101: 1644-1655.
2. Dellinger RP, Carlet JM, Masur H., et al. for the Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for the management of severe sepsis and septic shock. Crit Care Med. 2004 ; 32: 858-873.
3. Martin GS, Mannino DM, Eaton S., Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003 ; 348: 1546-1554.
4. National Center for Health Statistics. National Vital Statistics Reports. Table E: Deaths and Percentages of Total Deaths for the Ten Leading Causes Of Death, by Race: United States. Vol. 52 Hyattsville, MD: National Center for Health Statistics ; 2003: 9.
5. Angus DC, Linde-Zwirble WT, Lidicker J., Clermont G., Carcillo J., Pinsky MR Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated cost of care. Crit Care Med. 2001 ; 29: 1303-1310.
6. Rangel-Frausto MS, Pittet D., Hwang T., Woolson RF, Wenzel RP The dynamics of disease progression in sepsis: Markov modeling describing the natural history and the likely impact of effective antisepsis agents. Clin Infec Dis. 1998 ; 27: 185-190.
7. Annane D., Aegerter P., Jars-Guincestre MC, Guidet B., CUB-Réa Network. Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med. 2003 ; 168: 165-172.
8. Alberti C., Brun-Buisson C., Burchardi H., et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. 2002 ; 28: 108-121.
9. Bernard B., Grange JD, Khac EN, Amiot X., Opolon P., Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology. 1999 ; 29: 1655-1661.
10. Sharma VK, Howden CW Prophylactic antibiotic administration reduces sepsis and mortality in acute necrotizing pancreatitis: a meta-analysis. Pancreas. 2001 ; 22: 28-31.
11. van den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001 ; 345: 1359-1367.
12. de Jonge E., Schultz MJ, Spanjaard L., et al. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet. 2003 ; 362: 1011-1016.
13. Foxwell AR, Cripps AW, Dear KBG. Haemophilus influenzae oral whole cell vaccination for preventing acute exacerbations of chronic bronchitis. Cochrane Database Syst Rev. 2004 ; 3: CD001958.
14. Dear K., Holden J., Andrews R., Tatham D. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2004 ; 4: CD000422.
15. Cafiero F., Gipponi M., Bonalumi U., et al. Prophylaxis of infection with intravenous immunoglobulins plus antibiotic for patients at risk for sepsis undergoing surgery for colorectal cancer: results of a randomized, multicenter clinical trial. Surgery. 1992 ; 112: 24-31.
16. Douzinas EE, Pitaridis MT, Louris G., et al. Prevention of infection in multiple trauma patients by high-dose intravenous immunoglobulins. Crit Care Med. 2000 ; 28: 254-255.
17. Annane D., Bellissant E., Bollaert P., et al. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ. 2004 ; 329: 480.
18. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med. 1997 ; 336: 912-918.
19. Marshall JC Much stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov. 2003 ; 2: 391-405.
20. Jonsson BM, Ohlsson K., Rosengren M. Radioimmunological quantitation of the urinary trypsin inhibitor in normal blood and urine. Biol Chem Hoppe Seyler. 1989 ; 370: 1157-1161.
21. Zavaglia C., Airoldi A., Pinzello G. Antiviral therapy of HBV- and HCV-induced liver cirrhosis. J Clin Gastroenterol. 2000 ; 30: 234-241.
22. Nishiyama T., Aibiki M., Hanaoka K. The effects of ulinastatin, a human protease inhibitor, on the transfusion-induced increase of plasma polymolphonuclear granulocyte elastase. Anesth Analg. 1996 ; 82: 108-112.
23. Ohnishi H., Kosuzume H., Ashida Y., Kato K., Honjo I. Effects of urinary trypsin inhibitor on pancreatic enzyme and experimental acute pancreatitis. Dig Dis Sci. 1984 ; 29: 26-32.
24. Chen XM, Jiang HL, Zhou LF, et al. Immunomodulatory function of orally administered thymosin alpha1. J Zhejiang Univ Sci B. 2005 ; 6: 873-876.
25. Kullavanuaya P., Treeprasertsuk S., Thong-Ngam D., Chaermthai K., Gonlachanvit S., Suwanagool P. The combined treatment of interferon alpha-2a and thymosin alpha 1 for chronic hepatitis C: the 48 weeks end of treatment results. J Med Assoc Thai. 2001 ; 84 (suppl 1). S462 - S468.
26. Andreone P., Cursaro C., Gramenzi A., et al. In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C. J Viral Hepat. 2001 ; 8: 194-201.
27. Garaci E., Pica F., Rasi G., Favalli C. Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. Int J Immunopharmacol. 2000 ; 22: 1067-1076.
28. Saruc M., Ozden N., Turkel N., et al. Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. J Pharm Sci. 2003 ; 92: 1386-1395.
29. Nishiyama T., Hanaoka K. Do the effects of a protease inhibitor, ulinastatin, on elastase release by blood transfusion depend on interleukin 6? Crit Care Med. 2001 ; 29: 2106-2110.
30. Nishiyama T., Yokoyama T., Hanaoka K. Correlations between plasma levels of polymorphonuclear leukocyte elastase and coagulation and fibrinolysis parameters in patients undergoing major abdominal surgery. Anesth Res. 1996 ; 32: 369-372.
31. Pathan N., Hemingway CA, Alizadeh AA, et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet. 2004 ; 363: 203-209.
32. Yamamoto M., Takeda K., Akira S. TIR domain-containing adaptors define the specificity of TLR signaling. Mol Immunol. 2004 ; 40: 861-868.
33. Girardin SE, Philpott DJ The role of peptidoglycan recognition in innate immunity. Eur J Immunol. 2004 ; 34: 1777-1782.
34. Dziarski R. Peptidoglycan recognition proteins (PGRPs). Mol Immunol. 2004 ; 40: 877-886.
35. Sharma VK, Howden CW Prophylactic antibiotic administration reduces sepsis and mortality in acute necrotizing pancreatitis: a meta-analysis. Pancreas. 2001 ; 22: 28-31.
36. Sappington P., Yang R., Yang H., Tracey KJ, Delude RL, Fink MP HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology. 2002 ; 123: 790-702.
37. Bruewer M., Luegering A., Kucharzik T., et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis independent mechanisms. J Immun. 2003 ; 171: 6164-6172.
38. Abraham E., Reinhart K., Opal S., et al. OPTIMIST Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003 ; 290: 238-247.
39. Levi M., Dorffler-Melly J., Reitsma P., et al. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood. 2003 ; 101: 4823-4827.
40. Annane D., Bellissant E., Bollaert PE, Briegel J., Keh D., Kupfer Y. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ. 2004 ; 329: 480.
41. Minneci PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Intern Med. 2004 ; 141: 47-56.
42. Ziegler EJ, Fisher CJ, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind,placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med. 1991 ; 324: 429-436.
43. Greenberg RN, Wilson KM, Kunz AY, Wedel NI, Gorelick KJ Randomized, double-blind phase II study of anti-endotoxin antibody (E5) as adjuvant therapy in humans with serious gram-negative infections. Prog Clin Biol Res. 1991 ; 367: 179-186.
44. Warren HS, Amato SF, Fitting C., et al. Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J Exp Med. 1993 ; 177: 89-97.
45. Okabe H., Irita K., Kurosawa K., et al. Increase in the plasma concentration of reduced glutathione observed in rats with liver damage induced by lipopolysaccharide/D-galactosamine: effects of ulinastatin, a urinary trypsin inhibitor. Circ Shock. 1993 ; 41: 268-272.
46. Bochkov VN, Kadl A., Huber J., Gruber F., Binder BR, Leitinger N. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature. 2002 ; 419: 77-81.
47. van der Poll T., Coyle SM, Barbosa K., Braxton CC, Lowry SF Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin-10 production during human endotoxemia. J Clin Invest. 1996 ; 97: 713-719.
48. Pepys MB, Hirschfield GM C-reactive protein: a critical update. J Clin Invest. 2003 ; 111: 1805-1812.
49. Gabay C., Kushner I. Acute phase proteins and other systemic responses to inflammation. N Engl J Med. 1999 ; 340: 448-454.
50. The Cooperative Group of immunomodulatory Therapy of Sepsis, Lin HY Clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with ulinastatin and maipuxin. Zhonghua Yi Xue Za Zhi. 2007 ; 87: 451-457.